Members of the Global NASH/MASH Council (GNC) have recently published two major original manuscripts in Hepatology. The GNC Collaborators created the Global-MASLD project, a cohort of 17,792 biopsy-proven MASLD cases with extensive clinical, laboratory, non-invasive test (NIT) data, and long-term outcomes.
In the first manuscript, “Global Performance of Non-Invasive Tests in MASLD: Insights from the G-MASLD Study,” the group evaluates the performance of commonly used NITs across different regions of the world. The analysis shows that the diagnostic accuracy of NITs for fibrosis in MASLD varies geographically, with the Agile-3+ and Agile-4 composite scores demonstrating the highest accuracy (link to PDF).
The second manuscript, “Predictors of Fibrosis, Clinical Events, and Mortality in MASLD: Data from the Global-MASLD Study,” demonstrates that both histologic stage and fibrosis-related NITs are independent predictors of clinical outcomes in MASLD. Notably, the strength of association was greater for certain NITs than for histology (link to PDF).
Together, these studies highlight that NITs are the most clinically relevant predictors of outcomes in MASLD. Both studies support the use of NITs as key endpoints in clinical research and as the most meaningful measures for MASH clinical trials.
